Bristol-Myers Squibb, often referred to as BMS, is an American pharmaceutical company, headquartered in New York City.Bristol-Myers Squibb manufactures prescription pharmaceuticals in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders. Its mission is to "discover, develop and deliver innovative medicines that help patients prevail over serious diseases."BMS' primary R&D sites are located in Lawrence Township and Wallingford, Connecticut , with other sites in Hopewell and New Brunswick, New Jersey, and in Braine-l'Alleud, Belgium, Tokyo, and Bangalore, India. Wikipedia.
Bristol Myers Squibb | Date: 2017-01-25
Compounds of Formula (I), including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV: (I)
Bristol Myers Squibb | Date: 2017-03-15
The present invention provides compounds of Formula (I) or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments.
Bristol Myers Squibb | Date: 2016-11-02
Fibronectin type III (^(10)Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative ^(10)Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes ^(10)Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are ^(10)Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.
Bristol Myers Squibb | Date: 2016-10-18
The present invention provides isolated monoclonal antibodies that specifically bind LAG-3, and have optimized functional properties compared to previously described anti-LAG-3 antibodies, such as antibody 25F7 (US 2011/0150892 A1). These properties include reduced deamidation sites, while still retaining high affinity binding to human LAG-3, and physical (i.e., thermal and chemical) stability. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided, as well as immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies. The present invention also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which the antibodies are co-administered with at least one additional immunostimulatory antibody, is also provided.
Bristol Myers Squibb | Date: 2017-05-03
The present disclosure relates to methods for making asunaprevir, useful treatment of Hepatitis C virus (HCV) infection, and its intermediates.
Bristol Myers Squibb | Date: 2017-03-22
The application provides Fc fusion proteins having novel arrangements. In particular, the application provides Fc fusion proteins comprising a ^(10)Fn3 domain and a linker derived from the naturally occurring C-terminal tail regions of membrane bound or secretory immunoglobulins.
Bristol Myers Squibb | Date: 2017-02-01
A compound of formula I_(1) and R_(24) are described herein. The compounds are useful as inhibitors of potassium channel function and in the treatment and prevention of arrhythmia, I_(Kur)-associated disorders, and other disorders mediated by ion channel function.
Bristol Myers Squibb | Date: 2017-04-19
The present invention provides innovative proteins that bind to insulin-like growth factor-I receptor (IGF-IR), as well as other important proteins. The invention also provides innovative proteins in pharmaceutical preparations and derivatives of such proteins and the uses of same in diagnostic, research and therapeutic applications. The invention further provides cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins.
Bristol Myers Squibb | Date: 2017-01-11
A method of treating an inflammatory bowel disease is provided. The method comprises administration of an antibody polypeptide that specifically binds a novel epitope of human CD40. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides may be fusions of a domain antibody (dAb) comprising a single VL or VH domain and an Fc domain.
Bristol Myers Squibb | Date: 2017-02-22
The present disclosure generally relates to inhibitors of the PD-l/PD- Ll protein/protein and CD80/PD-L1 protein/protein interactions useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.